CAJ | 학술논문

目的观察低剂量吉西他滨联合卡铂治疗老年晚期非小细胞肺癌的疗效.方法 35例65岁以上的晚期非小细胞肺癌患者应用吉西他滨800～1000 mg/m2第1、8天,静脉滴注30 min,卡铂300 mg/m2第1天静脉滴注,3周重复；观察疗效.结果 35例患者均共完成106个化疗周期,完全缓解0例,部分缓解10例,稳定13例,进展12例,总有效率28.6％；疾病控制率65.7％,中位疾病进展时间5.1个月,中位生存期11.5个月,1年生存率为34.3％(12/35).不良反应主要为白细胞减少、血小板减少、贫血、乏力,但均可耐受.结论低剂量吉西他滨联合卡铂治疗老年晚期非小细胞肺癌的疗效肯定,且患者耐受性好.
목적 관찰저제량길서타빈연합잡박치료노년만기비소세포폐암적료효.방법 35례65세이상적만기비소세포폐암환자응용길서타빈800～1000 mg/m2제1、8천,정맥적주30 min,잡박300 mg/m2제1천정맥적주,3주중복；관찰료효.결과 35례환자균공완성106개화료주기,완전완해0례,부분완해10례,은정13례,진전12례,총유효솔28.6％；질병공제솔65.7％,중위질병진전시간5.1개월,중위생존기11.5개월,1년생존솔위34.3％(12/35).불량반응주요위백세포감소、혈소판감소、빈혈、핍력,단균가내수.결론 저제량길서타빈연합잡박치료노년만기비소세포폐암적료효긍정,차환자내수성호.
Objective To investigate the effect and safety of combination of chemotherapy with gemcitabine and carboplatin in the treatment of advanced non-small cell lung cancer.Methods Thirty-five patients with advanced non-small cell lung cancer received gemcitabine 800-1000 mg/m2 in half an hour at day 1 and 8,and carboplatin 300 mg/m2 at day 1 for at least two cycles.The response and toxicity of chemotherapy were evaluated and survival rate was followed up.Results Valuable cases partial response was observed in 10 cases,no change was seen in 13 cases,progress disease was seen in 12 cases.Overall response rate was 28.6％ and median survival time was 11.5 months and 1 year survival rate was 34.3％ (12/35).The most common toxicities were:leucopenia,thrombocytopenia and anaemiaand fatigue.These toxicities were well-tolerated.Conclusion The regiment of low-dose gemcitabine combined with carboplation is active and well tolerated in treating elderly patients with advanced non-small cell lung cancer.